AstraZeneca (NASDAQ: AZN), a U.K.-based pharmaceutical giant, is one of them; its stock is up by an impressive 16% since ...

Independent Advisor Alliance increased its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 13.0% in the fourth ...

A new sub-analysis of data from a phase 3 trial shows AstraZeneca’s Brilinta cuts the risk of cardiovascular death by 29% in high risk patients. The new study will be presented at the European ...

The FDA has granted a fast review of AstraZeneca’s cardiovascular diseases drug Brilinta (ticagrelor) in the new indication that aims to reduce the chances of patients having recurring strokes.

All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.

In the ULTIMATE-DAPT trial, presented at the American College of Cardiology Scientific Session in 2024, 1 month of DAPT followed by ticagrelor (Brilinta, AstraZeneca) monotherapy reduced bleeding ...

and ticagrelor (Brilinta, AstraZeneca) or prasugrel is recommended over clopidogrel for those undergoing PCI, according to the document. “Changes to DAPT duration are dependent on bleeding risks ...

Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about ...